On the twenty fifth of September, Orbimed Advisors bought 1.2 million Prelude Therapeutics Incorporat (PRLD) shares for $23 million at a median worth of $19.00 per share.
Shares of Prelude Therapeutics Incorporat are up 57.52% because the transaction.
Orbimed Advisors’s holding in Prelude Therapeutics Incorporat established a brand new holding of about 917 thousand shares with the acquisition.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or harm because of reliance on the knowledge together with information, quotes, charts and purchase/promote alerts contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding kinds potential.